This study showed that after GBM patients failed Temodar on the standard schedule, trying Temodar again in a dose-intense schedule of 21 days on and 7 days off did not help much. Only 13% had even a small response, and only 11% of patients were progression free 6 months later.
One interesting note on this paper is that they were incorrect on what the standard therapy of a glioblastoma is. Standard thereapy is defined by the National Comprehensive Cancer Network guidelines as well as the FDA approvals of treatments. Both say that the standard treatment of GBM now includes Gliadel Wafer implantation at both the initial surgery as well as subsequent surgeries, and the use of the Novocure Novo-TTF 100a system at recurrence.
NCCN Guidelines can be found at: http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
Posted on: 07/03/2013
for full text.
Oxford JournalsLife Sciences & Medicine Neuro-Oncology Volume 15, Issue 7Pp. 930-935.
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma
Andrew D. Norden, Glenn J. Lesser, Jan Drappatz, Keith L. Ligon, Samantha N. Hammond, Eudocia Q. Lee, David R. Reardon, Camilo E. Fadul, Scott R. Plotkin, Tracy T. Batchelor, Jay-Jiguang Zhu, Rameen Beroukhim, Alona Muzikansky, Lisa Doherty, Debra Lafrankie, Katrina Smith, Vida Tafoya, Rosina Lis, Edward C. Stack, Myrna R. Rosenfeld and Patrick Y. Wen
+ Author Affiliations
Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (A.D.N., S.N.H., E.Q.L., L.D., D.L., K.S., V.T., P.Y.W.); Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts (A.D.N., E.Q.L., P.Y.W.); Section of Hematology and Oncology, Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina (G.J.L.); Division of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (J.D.); Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts (K.L.L., R.B.); Neuro-oncology Program, Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire (C.E.F.); Massachusetts General Hospital Cancer Center, Pappas Center for Neuro-Oncology, Boston, Massachusetts (S.R.P., T.T.B.); The Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center at Houston, Mischer Neuroscience Institute, Memorial Hermann Hospital, Houston, Texas (J-J.Z.); Massachusetts General Hospital Biostatistics Center, Boston, Massachusetts (A.M.), Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (R.L., E.C.S., K.L.L.), Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (R.L., E.C.S., K.L.L.); Division of Neuro-Oncology, Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania (M.R.R.)
Corresponding Author: Patrick Y. Wen, MD, Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, 450 Brookline Ave., Boston, MA 02215 (email@example.com).
Received December 17, 2012.
Accepted February 20, 2013.
Background Among patients with glioblastoma (GBM) who progress on standard temozolomide, the optimal therapy is unknown. Resistance to temozolomide is partially mediated by O6-methylguanine-DNA methyltransferase (MGMT). Because MGMT may be depleted by prolonged temozolomide administration, dose-intense schedules may overcome resistance.
Methods This was a multicenter, phase 2, single-arm study of temozolomide (75–100 mg/m2/day) for 21 days of each 28-day cycle. Patients had GBM in first recurrence after standard therapy. The primary end point was 6-month progression-free survival (PFS6).
Results Fifty-eight participants were accrued, 3 of whom were ineligible for analysis; one withdrew before response assessment. There were 33 men (61%), with a median age of 57 years (range, 25–79 years) and a median Karnofsky performance score of 90 (range, 60–100). Of 47 patients with MGMT methylation results, 36 (65%) had methylated tumors. There were 7 (13%) partial responses, and PFS6 was only 11%. Response and PFS did not depend on MGMT status; MSH2, MLH1, or ERCC1 expression; the number of prior temozolomide cycles; or the time off temozolomide. Treatment was well tolerated, with limited grade 3 neutropenia (n = 2) or thrombocytopenia (n = 2).
Conclusions Dose-intense temozolomide on this schedule is safe in recurrent GBM. However, efficacy is marginal and predictive biomarkers are needed.
Click HERE to return to brain tumor news headlines.